Grading in soft tissue tumors: principles and problems.
Histologic grading has been considered the most important prognostic factor for soft tissue sarcomas. Several grading systems have been proposed based on the assessment of morphologic features in heterogeneous groups of sarcomas. Currently, the French Federation of Cancer Centers (FNCLCC) and the National Cancer Institute (NCI) grading systems are the most commonly used. These systems are based on a few morphologic predictors of biologic behavior, which is justifiable because of the rarity of soft tissue sarcomas. Nonetheless, over- or underestimation of prognosis may occur because of an uneven representation of specific sarcomas with rather distinct biologic behaviors among studies of grading systems. In addition, lack of standardization of morphologic criteria and frequent omission of the influence of clinical factors on the final survival analyses preclude universal acceptance of a particular grading system. New advances in diagnostic imaging, quantitative morphometric technologies, cytogenetics, and molecular genetics, allied with alternative analytic data systems, may provide better validation, reproducibility, and prognostic capabilities for current and future grading systems. This article summarizes and critically analyzes the various important grading systems that have thus far been proposed and suggests alternatives for the elaboration of more reproducible systems with higher predictive capabilities.
Oliveira
A M
AM
Division of Anatomic Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Nascimento
A G
AG
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001707:Biopsy, Needle; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D018219:Histiocytoma, Benign Fibrous / Q000473:pathology; D006801:Humans; D007890:Leiomyosarcoma / Q000473:pathology; D008080:Liposarcoma / Q000473:pathology; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000473:pathology; D012306:Risk; D012509:Sarcoma / Q000401:mortality / Q000473:pathology*; D013584:Sarcoma, Synovial / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D013997:Time Factors